APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer’s disease
The ε4 allele of Apolipoprotein (APOE4) is the strongest genetic risk factor for Alzheimer’s disease (AD), the most common form of dementia. Cognitively normal APOE4 carriers have developed amyloid β (Aβ) plaques and cerebrovascular, metabolic and structural deficits decades before showing the cognitive impairment. Interventions that can inhibit Aβ retention and restore the brain functions […]